Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke.

Eur Stroke J · 2023 · PMC10472948 · PMID 37641549

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, a systematic review demonstrated that tenecteplase in LVO patients showed a trend to more favorable outcomes (odds ratio 1.49, 95% CI 0.95–2.32 for mRS0–1) and lower mortality at 90 days after stroke (odds ratio 0.93, 95% CI 0.31–2.80). 6 Gao et al. 15 reported that tenecteplase was dominant for LVO patients before EVT in both within-trial and long-term model analyses.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.